Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.
Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.
Not yet recruiting · NCT07616362 · Registry updated 2026-06-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. | Borderline Resectable Pancreatic Ductal Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-06-11 | NCT07616362 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Federation Francophone de Cancerologie Digestive | 19 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hopital Nord Chu Saint Etienne | Saint-Priest-en-Jarez | France | 3 |
| Hôpital Beaujon | Clichy | France | 16 |
| Hôpital Lyon Sud | Pierre-Bénite | France | 4 |
| Hôpital Rangueil | Toulouse | France | 7 |
| Institut Paoli Calmettes | Marseille | France | 49 |